胰高血糖素样肽-1受体激动剂用于戒烟的治疗潜力
本综述探讨GLP-1受体激动剂(GLP-1RAs)用于戒烟的治疗潜力。临床前研究显示GLP-1RAs调节尼古丁奖赏、减少尼古丁自我给药并防止戒断相关暴食;早期临床研究提示GLP-1RAs可防止戒烟后体重增加,并可能改善戒烟或减少渴求。结合其心血管代谢风险降低作用,GLP-1药物被视为吸烟人群有前景的治疗类别。
要点
- GLP-1RAs临床前可调节尼古丁奖赏、减少自我给药并防止戒断相关暴食。
- 早期临床研究提示GLP-1RAs防止戒烟后体重增加,可能改善戒烟或减少渴求。
- 代谢障碍或精神障碍患者可能是GLP-1药物获益重要的临床亚组。
核心结论
- GLP-1RAs通过调节尼古丁奖赏、减少自我给药和防止戒断相关暴食,结合心血管代谢风险降低作用,成为吸烟人群有前景的治疗类别。
研究设计与样本
- 本综述汇总临床前研究、随机试验及其他人体研究,探讨GLP-1-based疗法用于戒烟的治疗潜力。
主要发现
- 临床前研究发现GLP-1RAs调节尼古丁奖赏、减少尼古丁自我给药并防止戒断相关暴食。
- 早期临床研究提示GLP-1RAs防止戒烟后体重增加,并可能改善戒烟或减少渴求。
临床怎么用
- GLP-1药物可考虑用于吸烟人群,尤其是代谢障碍或精神障碍患者,以降低烟草相关发病和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 (GLP-1) therapies are under investigation for a growing number of neuropsychiatric conditions, including substance use disorders. Cigarette smoking accounts for the largest proportion of substance use-related morbidity and mortality, in part reflecting increased risk for cardiometabolic disease among people who smoke. Given modest quit rates with approved smoking cessation therapies, medications with novel mechanisms of action are needed to expand the available monotherapy and combination treatment options. Treatments that prevent postcessation weight gain could further reduce relapse and cardiometabolic risks following smoking cessation. Preclinical findings have shown that GLP-1 receptor agonists (GLP-1RAs) modulate nicotine reward, reduce nicotine self-administration, and prevent withdrawal-related hyperphagia. Early clinical investigations suggest that GLP-1RAs prevent postcessation weight gain while potentially improving cessation or reducing craving. These findings, combined with the efficacy of GLP-1RAs for cardiometabolic risk reduction, position GLP-1 medicines as a promising therapeutic class for people who smoke. This review addresses the therapeutic potential of GLP-1-based therapies for smoking cessation, emphasizing emerging findings from randomized trials and other human investigations. Potential neural mechanisms for effects of GLP-1RAs on nicotine reward are reviewed, and priorities for future clinical and translational studies are discussed. Individuals with metabolic disorders or psychiatric disorders are proposed as clinical subgroups for which therapeutic benefits of GLP-1 medicines may prove important based on elevated risk for tobacco-related morbidity and mortality.
引用
- Hendershot CS, Simmons WK, Jha MK, et al. Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation. Biol Psychiatry. 2026. PMID: 41967661. doi:10.1016/j.biopsych.2026.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。